Kynam Capital Management, LP Protagonist Therapeutics, Inc Transaction History
Kynam Capital Management, LP
- $1.28 Billion
- Q2 2024
A detailed history of Kynam Capital Management, LP transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Kynam Capital Management, LP holds 800,000 shares of PTGX stock, worth $35.9 Million. This represents 2.16% of its overall portfolio holdings.
Number of Shares
800,000
Previous 1,144,242
30.08%
Holding current value
$35.9 Million
Previous $33.1 Million
16.26%
% of portfolio
2.16%
Previous 3.47%
Shares
8 transactions
Others Institutions Holding PTGX
# of Institutions
195Shares Held
58.7MCall Options Held
20.8KPut Options Held
109K-
Farallon Capital Management LLC San Francisco, CA5.84MShares$262 Million0.98% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$259 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.29MShares$238 Million3.06% of portfolio
-
Bvf Inc San Francisco, CA3.32MShares$149 Million3.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.24MShares$146 Million0.0% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.21B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...